Krebs Biochemicals to hold 34th AGM on Sep 29, 2026, with e-voting facility
Krebs Biochemicals will hold its 34th AGM on September 29, 2026, via VC/OAVM. Shareholders can e-vote from September 25-28, 2026. The agenda includes approving FY26 financial statements, re-appointing directors, and seeking approval for related party transactions up to ₹120 crore with Ipca Laboratories.
The announcement pertains to a procedural event (AGM) and standard corporate governance matters. It does not involve any new financial performance data, significant strategic changes, or material business developments that would have a substantial impact on the company's valuation.
The announcement is a routine notice regarding the Annual General Meeting and related voting procedures. It does not contain any information that would significantly impact the company's stock price or financial performance.
Krebs Biochemicals and Industries Limited has announced that its 34th Annual General Meeting (AGM) will be held on Tuesday, September 29, 2026, at 11:30 a.m. The meeting will be conducted through Video Conferencing / Other Audio Visual Means (VC/OAVM).
The company has provided a remote e-voting facility for its shareholders. The remote e-voting period will commence on Friday, September 25, 2026, at 9:00 a.m. and conclude on Monday, September 28, 2026, at 5:00 p.m.
The AGM agenda includes receiving and adopting the Audited Balance Sheet, Statement of Profit & Loss, and Cash Flow Statement for the financial year ended March 31, 2026. It also includes the re-appointment of directors Dr. R T Ravi and Mr. Manish Kumar Jain, who are retiring by rotation. Special business includes seeking shareholder approval for related party transactions with Ipca Laboratories Limited, with an aggregate value not exceeding ₹120 Crore for any financial year, and ratifying the remuneration payable to the Cost Auditors for the financial year 2026-27, set at ₹1,00,000 plus service tax and expenses.
The Annual Report 2025-26, which includes the Notice of the 34th AGM, has been sent to shareholders in electronic mode and is also available on the company's website, www.krebsbiochem.com, and the stock exchanges' websites.
What to do with a filing like this
Krebs Biochemicals and Industries Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krebs Biochemicals and Industries Limited. Read the original for the full detail.